# US 2010/0168141 A1 · Azetidine analogues nucleosidase and phosphorylase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168141 A1
- Document ID: US20100168141A1
- Status: Published application
- Kind: A1
- Application number: 12/448,397
- Filed: 2007-12-21
- Published: 2010-07-01
- Earliest claimed: 2006-12-22
- Assignees: Industrial Research Limited; Albert Einstein College of Medicine of Yeshiva University
- Inventors: Gary Brian Evans; Richard Hubert Furneaux; Ben William Greatrex; Vern L. Schramm; Peters Charles Tyler
- Web page: https://patentgrep.com/patent/US20100168141A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 31/04: Antibacterial agents
- A61P 33/00: Antiparasitic agents
- A61P 33/02: Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P 33/06: Antimalarials
- A61P 35/00: Antineoplastic agents
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Azetidine analogues of nucleosidase and nucleoside phosphorylase inhibitors having the general formula (I), the use of these compounds as pharmaceuticals, pharmaceutical compositions containing the compounds, methods of treating certain diseases using the compounds, processes for preparing the compounds, and intermediates useful in the preparation of the compounds wherein W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ; Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q; Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy; R1 is a radical of the formula (II) or R1 is a radical of the formula (III) A is selected from N, CH and CR2, where R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl; B is selected from hydroxy, NH2, NHR6, SH, hydrogen and halogen, where R6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; D is selected from hydroxy, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen; E is selected from N and CH; G is a C1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent; or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

## Claims

### Claim 1

A compound of formula (I):
wherein:
W and X are each independently selected from hydrogen, CH2OH, CH2OQ and CH2SQ;
Y and Z are each independently selected from hydrogen, halogen, CH2OH, CH2OQ, CH2SQ, SQ, OQ and Q;
Q is an alkyl, aralkyl or aryl group each of which may be optionally substituted with one or more substituents selected from hydroxy, halogen, methoxy, amino, or carboxy;
R1 is a radical of the formula (II)
or R1 is a radical of the formula (III)
A is selected from N, CH and CR2, where R2 is selected from halogen, alkyl, aralkyl, aryl, OH, NH2, NHR3, NR3R4 and SR5, where R3, R4 and R5 are each alkyl, aralkyl or aryl groups optionally substituted with hydroxy or halogen, and where R2 is optionally substituted with hydroxy or halogen when R2 is alkyl, aralkyl or aryl;
B is selected from hydroxy, NH2, NHR6, SH, hydrogen and halogen, where R6 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen;
D is selected from hydroxy, NH2, NHR7, hydrogen, halogen and SCH3, where R7 is an alkyl, aralkyl or aryl group optionally substituted with hydroxy or halogen;
E is selected from N and CH;
G is a C1-4 saturated or unsaturated alkyl group optionally substituted with hydroxy or halogen, or G is absent;
or a tautomer thereof, or a pharmaceutically acceptable salt thereof, or an ester thereof, or a prodrug thereof.

### Claim 2 (depends on 1)

A compound as claimed in claim 1 where W is CH2OH or CH2SQ.

### Claim 3 (depends on 2)

A compound as claimed in claim 2 where W is CH2SCH3.

### Claim 4 (depends on 1)

A compound as claimed in claim 1 where X is CH2OH or CH2SQ.

### Claim 5 (depends on 2)

A compound as claimed in claim 2 where W is CH2SCH3.

### Claim 6 (depends on 1)

A compound as claimed in claim 1 where Z is selected from hydrogen, halogen, CH2OH, CH2OQ and CH2SQ.

### Claim 7 (depends on 6)

A compound as claimed in claim 6 where Y or Z is CH2OH.

### Claim 8 (depends on 6)

A compound as claimed in claim 6 where Y or Z is CH2SQ or CH2OQ.

### Claim 9 (depends on 6)

A compound as claimed in claim 6 where either or both of Y or Z is Q.

### Claim 10 (depends on 6)

A compound as claimed in claim 6 where either or both of Y or Z is CH2OH.

### Claim 11 (depends on 1)

A compound as claimed in claim 1 where W and X are both hydrogen.

### Claim 12 (depends on 11)

A compound as claimed in claim 11 where either or both of Y or Z is CH2OH.

### Claim 13 (depends on 11)

A compound as claimed in claim 11 where either or both of Y or Z is CH2SQ.

### Claim 14 (depends on 1)

A compound as claimed in claim 1 where Y and Z are both hydrogen.

### Claim 15 (depends on 14)

A compound as claimed in claim 14 where either or both of Y or Z is CH2OH.

### Claim 16 (depends on 1)

A compound as claimed in claim 1 where G is CH2.

### Claim 17 (depends on 1)

A compound as claimed in claim 1 where R1 is a radical of the formula (II).

### Claim 18 (depends on 1)

A compound as claimed in claim 1 claims where R1 is a radical of formula (III).

### Claim 19 (depends on 1)

A compound as claimed in claim 1 where B is hydroxy or NH2.

### Claim 20 (depends on 1)

A compound as claimed in claim 1 where A is CH or N.

### Claim 21 (depends on 1)

A compound as claimed in claim 1 where D is H or NH2.

### Claim 22 (depends on 1)

A compound as claimed in claim 1 where E is N.

### Claim 23 (depends on 1)

A compound as claimed in claim 1 where, when any of Y, Z, B and D is halogen, each halogen is independently chlorine or fluorine.

### Claim 24 (depends on 1)

A compound as claimed in claim 1 which is:
i. 7-((2,4-bis(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
ii. 7-((3,3-bis(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
iii. 7-((2-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
iv. 7-((3-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
v. 7-((3-hydroxy-3-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
vi. 74(3-hydroxy-2-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
vii. 2-amino-7-((2,4-bis(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
viii. 2-amino-7-((3,3-bis(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
ix. 2-amino-74 (2-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
x. 2-amino-7-((3-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
xi. 2-amino-74 (3-hydroxy-3-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
xii. 2-amino-74 (3-hydroxy-2-(hydroxymethyl)azetidin-1-yl)methyl)-3H-pyrrolo[3,2-d]pyrimidin-4(5H)-one;
xiii. (1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-3-(methylthiomethyl)azetidin-3-yl)methanol;
xiv. 1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-3-(methylthiomethyl)azetidin-3-ol;
xv. (1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-4-(methylthiomethyl)azetidin-2-yl)methanol;
xvi. 7-((2-(methylthiomethyl)azetidin-1-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine;
xvii. 7-((3-(methylthiomethyl)azetidin-1-yl)methyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine; or
xviii. 1-((4-amino-5H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl)-2-(methylthiomethyl)azetidin-3-ol.

### Claim 25 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically effective excipient, diluent or carrier.

### Claim 26 (depends on 24)

A pharmaceutical composition comprising a compound of claim 24 and a pharmaceutically effective excipient, diluent or carrier.

### Claim 27 (depends on 1)

A method of treating, preventing or reducing the risk of a disease or condition in which it is desirable to inhibit PNP comprising administering a pharmaceutically effective amount of a compound of claim 1 to a patient requiring treatment.

### Claim 28 (depends on 27)

A method as claimed in claim 27 where the disease or condition is cancer, bacterial infection, parasitic infection, or a T-cell mediated disease.

### Claim 29 (depends on 28)

A method as claimed in claim 28 where the T-cell mediated disease is psoriasis, lupus, or arthritis.

### Claim 30 (depends on 27)

A method as claimed in claim 27 where the disease or condition is immunosuppression for organ transplantation.

### Claim 31 (depends on 28)

A method as claimed in claim 28 where the parasitic infection is a protozoan parasite infection.

### Claim 32 (depends on 31)

A method as claimed in claim 31 where protozoan parasite infection is caused by a parasite of the genera Giardia, Trichomonas, Leishmania, Trypanosoma, Crithidia, Herpetomonas, Leptomonas, Histomonas, Eimeria, Isopora and Plasmodium.

### Claim 33 (depends on 1)

A method of treating, preventing or reducing the risk of a disease or condition in which it is desirable to inhibit MTAP comprising administering a pharmaceutically effective amount of a compound of claim 1 to a patient requiring treatment.

### Claim 34 (depends on 33)

A method as claimed in claim 33 where the disease is cancer.

### Claim 35 (depends on 34)

A method as claimed in claim 34 where the cancer is prostate cancer or a head and neck tumour.

### Claim 36 (depends on 1)

A method of treating, preventing or reducing the risk of a disease or condition in which it is desirable to inhibit MTAN comprising administering a pharmaceutically effective amount of a compound of any one of claim 1 to a patient requiring treatment.

### Claim 37 (depends on 36)

A method as claimed in claim 36 where the disease or condition is a bacterial infection.
